Breast Cancer Cell-Derived Exosomal miR-92b-3p Promotes Tumor Angiogenesis and Metastasis by Suppressing PTEN in Vascular Endothelial Cells.
Cancer cells ship tumor-promoting molecules in tiny vesicles to blood vessels; tracking this could help detect metastasis risk earlier.
This preclinical study demonstrates that breast cancer cells transfer exosomal miR-92b-3p to vascular endothelial cells, where it suppresses PTEN to drive angiogenesis, endothelial barrier disruption, and metastasis in in vitro and murine xenograft models. TCGA validation shows miR-92b-3p upregulation correlates with advanced stage and poor survival, proposing it as a potential circulating exosomal liquid biopsy biomarker for breast cancer progression.
What the study was
- Study design
- Preclinical (in vitro + in vivo murine xenograft)
- Population
- Breast cancer cell lines; human microvascular endothelial cells (HMVECs); murine xenograft models; TCGA cohort for expression analysis
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Oncology Research
Why it surfaced
Preclinical exosomal miRNA study with TCGA clinical correlation; marginally relevant to T3 liquid biopsy watchlist via exosomal biomarker angle; evidence level is exploratory/preclinical.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.